Rhythm Pharmaceuticals, Inc. (RYTM) — SEC Filings
Rhythm Pharmaceuticals, Inc. (RYTM) — 49 SEC filings. Latest: 8-K (May 5, 2026). Includes 21 8-K, 8 SC 13G/A, 6 10-Q.
View Rhythm Pharmaceuticals, Inc. on SEC EDGAR
Overview
Rhythm Pharmaceuticals, Inc. (RYTM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: Rhythm Pharmaceuticals, Inc. announced on December 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Rhythm Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Rhythm Pharmaceuticals, Inc. (RYTM) has filed 21 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 8 SC 13G/A, 1 10-Q/A, 2 DEFA14A, 3 SC 13D/A, 1 SC 13D with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of RYTM's 36 recent filings, 1 were flagged as high-risk, 18 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $51.298M |
| Net Income | -$52.904M |
| EPS | -$0.82 |
| Debt-to-Equity | 1.42 |
| Cash Position | $416.1M |
| Operating Margin | -103.2% |
| Total Assets | $506.874M |
| Total Debt | $211.191M |
Key Executives
- Joseph Edelman
- Alexander Rakitin
Industry Context
Rhythm Pharmaceuticals operates in the specialized biopharmaceutical sector, focusing on rare genetic diseases. The industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Success hinges on developing novel therapies for unmet medical needs, often commanding premium pricing due to limited patient populations and therapeutic alternatives.
Top Tags
pharmaceuticals (11) · 8-K (5) · regulatory-filing (5) · amendment (5) · institutional-ownership (5) · sec-filing (4) · SEC Filing (4) · financial-reporting (4) · 10-Q (4) · financials (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue, Q3 2025 | $51.298M | Increased 54.2% from $33.251M in Q3 2024 |
| Product Revenue, YTD Sept 2025 | $137.518M | Increased 55.7% from $88.296M in YTD Sept 2024 |
| Net Loss, Q3 2025 | $52.904M | Widened from $43.641M in Q3 2024 |
| Accumulated Deficit | $1.3B | As of September 30, 2025, indicating historical losses |
| Cash & Short-term Investments | $416.1M | As of September 30, 2025, expected to fund operations for 12+ months |
| Research and Development Expenses, Q3 2025 | $46.027M | Increased from $37.931M in Q3 2024 |
| Selling, General, and Administrative Expenses, Q3 2025 | $52.425M | Increased from $35.377M in Q3 2024 |
| Common Shares Outstanding | 66,736,056 | As of October 31, 2025 |
| Net Loss Per Share, Q3 2025 | $0.82 | Increased from $0.73 in Q3 2024 |
| Total Stockholders' Equity | $148.817M | As of September 30, 2025, up from $21.729M at Dec 31, 2024 |
| Net Loss | $62.39M | for the three months ended June 30, 2025, a decrease from $63.91 million in Q2 2024 |
| Series A Convertible Preferred Stock | 150,000 | shares outstanding as of June 30, 2025 |
| Period End Date | 2025-06-30 | date of the current financial reporting period |
| Agreement Date | 2024-01-04 | date of rights agreement with LG Chem, Ltd. |
| Total Assets | $623.9M | As of March 31, 2025 |
Forward-Looking Statements
- {"claim":"Rhythm Pharmaceuticals' stock price will experience increased stability due to the significant institutional backing.","entity":"Rhythm Pharmaceuticals, Inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Perceptive Advisors may seek to engage with Rhythm Pharmaceuticals' management on strategic initiatives given their substantial ownership.","entity":"Perceptive Advisors LLC","targetDate":"Q3 2024","confidence":"low"}
- {"claim":"Other institutional investors may review PRIMECAP's reduced stake and potentially re-evaluate their own positions in Rhythm Pharmaceuticals, Inc.","entity":"Rhythm Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"The stock price of Rhythm Pharmaceuticals, Inc. could experience downward pressure if the market interprets PRIMECAP's reduction as a negative signal.","entity":"Rhythm Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rhythm Pharmaceuticals, Inc. (RYTM)?
Rhythm Pharmaceuticals, Inc. has 49 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RYTM filings?
Across 49 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Rhythm Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rhythm Pharmaceuticals, Inc.?
Key financial highlights from Rhythm Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RYTM?
The investment thesis for RYTM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rhythm Pharmaceuticals, Inc.?
Key executives identified across Rhythm Pharmaceuticals, Inc.'s filings include Joseph Edelman, Alexander Rakitin.
What are the main risk factors for Rhythm Pharmaceuticals, Inc. stock?
Of RYTM's 36 assessed filings, 1 were flagged high-risk, 18 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Rhythm Pharmaceuticals, Inc.?
Recent forward-looking statements from Rhythm Pharmaceuticals, Inc. include guidance on {"claim":"Rhythm Pharmaceuticals' stock price will experience increased stability due to the significant institutional b and 3 other predictions.